Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cholesterol Combo Therapy Will Likely Be More Prominent In ATP IV

Executive Summary

Treating cholesterol with a combination of statins and fibrates, niacin, or bile acid sequestrants may play a larger role in the next round of Adult Treatment Panel guidelines.

You may also be interested in...



Schering-Plough Zetia Could Be More Important Growth Product Than Claritin

Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16

Schering-Plough Zetia Could Be More Important Growth Product Than Claritin

Schering-Plough's cholesterol agent Zetia could be an even larger growth driver than Claritin, CEO Richard Kogan told analysts at the company's annual meeting on July 16

Cholesterol Therapy Guidelines Stress Need To Consider Cost, Treat To Goal

The National Cholesterol Education Program treatment guidelines encourage physicians to restrict drug therapy only to high risk patients - but expand the definition of high risk to include as many as 36 mil. people in the U.S.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel